Page last updated: 2024-12-05

3,3'-diindolylmethane

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Occurs in Manufacturing Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

3,3'-Diindolylmethane (DIM) is a naturally occurring compound found in cruciferous vegetables like broccoli, cauliflower, and Brussels sprouts. It is formed when indole-3-carbinol (I3C), another compound found in these vegetables, is broken down in the body. DIM has garnered significant research interest due to its potential health benefits, particularly in the areas of cancer prevention and hormone regulation. Research suggests that DIM may exhibit anti-cancer activity by influencing the metabolism of estrogen, a hormone linked to certain types of cancers. It is thought to modulate estrogen receptor activity and potentially promote the detoxification of harmful estrogen metabolites. DIM's impact on estrogen metabolism has also led to investigations of its role in managing conditions like endometriosis and fibroids. Notably, DIM is synthesized by the acid-catalyzed dimerization of indole-3-carbinol. Studies exploring its efficacy and safety are ongoing, and further research is needed to fully understand its mechanisms of action and potential therapeutic applications.'

3,3'-diindolylmethane: anti-inflammatory from edible cruciferous vegetables; a cytochrome P-450 antagonist [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID3071
CHEMBL ID446452
CHEBI ID50182
SCHEMBL ID325162
MeSH IDM0066345

Synonyms (114)

Synonym
CBIOL_001839
BRD-K37846922-001-05-2
nsc-708486
NCI60_038418
BIO2_000010
CBDIVE_010856
BIO1_000614
BIO1_001103
BIO2_000490
BIO1_000125
SPECTRUM5_001955
3,3'-methylenebis(1h-indole)
1968-05-4
bis-1h-indol-3-ylmethane
CHEBI:50182 ,
diindolylmethane
HSCI1_000069
BSPBIO_003589
OPREA1_740951
IDI1_033760
DIM ,
nsc708486
NCGC00095348-01
NCGC00095348-03
NCGC00095348-02
NCGC00095348-04
1h-indole, 3,3'-methylenebis-
3,3'-methylenebis-1h-indole
3,3'-diindolymethane
ccris 5806
3,3'-diindolylmethane
KBIO3_000020
KBIOGR_000010
KBIOSS_000010
KBIO2_000010
KBIO3_000019
KBIO3_003002
KBIO2_005146
KBIO2_002578
SPBIO_001722
SPECTRUM2_001711
SPECTRUM3_001989
SPECTRUM1505331
OPREA1_472633
BSPBIO_001290
NCGC00095348-05
NCGC00095348-06
3,3,-diindolylmethane
D-3720
3-diindolyl methane
STK263696
3,3'-methanediylbis(1h-indole)
3,3'-di(indol-3-yl)methane
AC-11611
HMS1989A12
arundine
3,3-diindolylmethane
CHEMBL446452
BML3-F11
HMS1361A12
HMS1791A12
M1399
3,3'-methylenediindole
di-3-indolylmethane
3-(1h-indol-3-ylmethyl)-1h-indole
AKOS003627372
di(1h-indol-3-yl)methane
S4728
CCG-39861
ssz9hqt61z ,
hb 236
infemin
plant indole
unii-ssz9hqt61z
FT-0614061
NCGC00095348-07
AM84671
diindolylmethane, 3,3'-
diindolylmethane [vandf]
3,3'-diindolylmethane [who-dd]
GR-207
HY-15758
CS-1652
SCHEMBL325162
KS-5266
3,3'-di-indolylmethane
smr001828114
MLS006011847
3,3'-diindolylmethane (dim)
HMS3402A12
mfcd00195766
DTXSID8037047
3,3'-diindolylmethane, aldrichcpr
3,3'-diindolylmethane, >=98% (hplc)
gtpl11208
3,3'-diindolylmethane, analytical standard
di(3-indolyl)methane
DB11875
diidolylmethane
Q4634053
SY038972
BCP00470
BRD-K37846922-001-09-4
BRD-K37846922-001-06-0
A16321
SB16901
33'-diindolylmethane
3,3 inverted exclamation marka-diindolylmethane
33diindolylmethyle
EN300-1717487
3-[(1h-indol-3-yl)methyl]-1h-indole
3-3-diindolylmethane
dim;arundine;hb 236
Z56791159

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" This study examined the potential of these phytochemicals to reduce the adverse effects of E2 on PCa."( 3,3'-Diindolylmethane and genistein decrease the adverse effects of estrogen in LNCaP and PC-3 prostate cancer cells.
Auborn, KJ; Bradlow, HL; Sepkovic, D; Smith, S, 2008
)
1.79
"Diindolylmethane seems to have no adverse affects on the rat even when given in doses 3x what we propose to be therapeutic."( A controlled safety study of diindolylmethane in the immature rat model.
Elackattu, AP; Feng, L; Wang, Z, 2009
)
0.35
" Although extensive studies have only focused on DIM's beneficial effects, the toxic effects of DIM on the immune systems have not been clearly elucidated."( 3,3'-Diindolylmethane induces immunotoxicity via splenocyte apoptosis in neonatal mice.
Cho, A; Cho, SD; Islam, MR; Kim, B; Kim, J; Kim, JH; Lee, JW; Lim, CW; Roh, YS, 2011
)
1.81

Pharmacokinetics

ExcerptReferenceRelevance
" A physiologically based pharmacokinetic (PBPK) model was developed to characterize the pharmacokinetic properties of the two different formulations."( Physiological modeling of formulated and crystalline 3,3'-diindolylmethane pharmacokinetics following oral administration in mice.
Anderton, MJ; Gescher, A; Mager, DE; Manson, MM; Steward, WP; Verschoyle, R; Williams, ML, 2004
)
0.57
" Mean Cmax for DIM increased from 61 ng/mL at the 400-mg I3C dose to 607 ng/mL following a 1,000-mg dose."( Single-dose and multiple-dose administration of indole-3-carbinol to women: pharmacokinetics based on 3,3'-diindolylmethane.
Arneson, DW; Crowell, JA; Gray, JC; Hurwitz, A; Mayo, MS; Putnam, WC; Reed, GA; Smith, HJ; Sullivan, DK, 2006
)
0.55
" Despite rapidly increasing knowledge regarding mechanisms responsible for the chemopreventive properties of DIM-C-pPhC6H5, there have been relatively few studies determining the absorption and pharmacokinetic properties of DIM-C-pPhC6H5 to explore its clinical utility."( Pharmacokinetic evaluation and in vitro-in vivo correlation (IVIVC) of novel methylene-substituted 3,3' diindolylmethane (DIM).
Chougule, MB; Patel, AR; Safe, S; Singh, M; Spencer, SD, 2012
)
0.38
"The pharmacokinetic absorption model presented represents a useful basis for obtaining plasma level predictability for poorly bioavailable, highly lipophilic drugs, such as the DIM analog DIM-C-pPhC6H5."( Pharmacokinetic evaluation and in vitro-in vivo correlation (IVIVC) of novel methylene-substituted 3,3' diindolylmethane (DIM).
Chougule, MB; Patel, AR; Safe, S; Singh, M; Spencer, SD, 2012
)
0.38
" We postulated that the pharmacokinetic behavior of C-DIM compounds after oral administration would correlate with neuroprotective efficacy in vivo in a mouse model of Parkinson's disease."( Neuroprotective efficacy and pharmacokinetic behavior of novel anti-inflammatory para-phenyl substituted diindolylmethanes in a mouse model of Parkinson's disease.
Colagiovanni, D; De Miranda, BR; Gustafson, DL; Hansen, RJ; Lunghofer, PJ; Miller, JA; Safe, S; Tjalkens, RB, 2013
)
0.39
" In this study, we sought to characterize the pharmacokinetics of DIM and to build a pharmacokinetic (PK) and pharmacodynamic (PD) model of the DIM-induced gene expression of phase II drug metabolizing enzymes (DME), which potentially links DIM's molecular effects to its in vivo chemopreventive efficacy."( Pharmacokinetics and pharmacodynamics of 3,3'-diindolylmethane (DIM) in regulating gene expression of phase II drug metabolizing enzymes.
Androulakis, IP; Boyanapalli, S; Gounder, M; Huang, Y; Kagan, L; Khor, TO; Kong, AN; Lin, H; Su, ZY; Wang, H; Wu, TY; Zhang, C, 2015
)
0.68

Bioavailability

ExcerptReferenceRelevance
" Relative drug exposure and absorption parameters suggest that BioResponse-DIM exhibited approximately 50% higher bioavailability than the crystalline formulation."( Physiological modeling of formulated and crystalline 3,3'-diindolylmethane pharmacokinetics following oral administration in mice.
Anderton, MJ; Gescher, A; Mager, DE; Manson, MM; Steward, WP; Verschoyle, R; Williams, ML, 2004
)
0.57
" We found that BioResponse DIM (B-DIM), a formulated DIM with higher bioavailability, inhibited angiogenesis and invasion by reducing the bioavailability of vascular endothelial growth factor (VEGF) via repressing extracellular matrix-degrading proteases, such as matrix metalloproteinase (MMP)-9 and urokinase-type plasminogen activator (uPA), in human prostate cancer cells and reduced vascularity (angiogenesis) in vivo using Matrigel plug assay."( Inhibition of angiogenesis and invasion by 3,3'-diindolylmethane is mediated by the nuclear factor-kappaB downstream target genes MMP-9 and uPA that regulated bioavailability of vascular endothelial growth factor in prostate cancer.
Banerjee, S; Kong, D; Li, Y; Sarkar, FH; Wang, Z, 2007
)
0.6
" However, some of these agents have poor bioavailability and many of the in-depth studies into their mechanisms of action have been carried out in vitro using doses which are unachievable in humans."( Predicting the physiological relevance of in vitro cancer preventive activities of phytochemicals.
Andreadi, CK; Foreman, BE; Howells, LM; Hudson, EA; Manson, MM; Moiseeva, EP; Neal, CP; Sun, YY, 2007
)
0.34
" In the present study, we determined the effects of 3,3'-diindolylmethane (Bioresponse BR-DIM referred to as B-DIM), a formulated DIM with greater bioavailability on cell viability and apoptosis with erlotinib in vitro and in vivo using an orthotopic animal tumor model."( Apoptosis-inducing effect of erlotinib is potentiated by 3,3'-diindolylmethane in vitro and in vivo using an orthotopic model of pancreatic cancer.
Ahmad, A; Ali, S; Banerjee, S; El-Rayes, BF; Philip, PA; Sarkar, FH, 2008
)
0.84
" An important development has been the availability of DIM formulation with superior bioavailability for humans."( Attenuation of multi-targeted proliferation-linked signaling by 3,3'-diindolylmethane (DIM): from bench to clinic.
Banerjee, S; Bao, B; Hillman, GG; Kong, D; Sarkar, FH; Wang, Z,
)
0.37
" The saturation model obtained accounts for a nonlinear change in C(max)/Dose, and the absolute bioavailability (0."( Pharmacokinetic evaluation and in vitro-in vivo correlation (IVIVC) of novel methylene-substituted 3,3' diindolylmethane (DIM).
Chougule, MB; Patel, AR; Safe, S; Singh, M; Spencer, SD, 2012
)
0.38
" We previously reported that a formulated DIM (BR-DIM; hereafter referred as B-DIM) with higher bioavailability was able to induce apoptosis and inhibit cell growth, angiogenesis, and invasion of prostate cancer cells."( Activation of AMP-activated protein kinase by 3,3'-Diindolylmethane (DIM) is associated with human prostate cancer cell death in vitro and in vivo.
Banerjee, S; Chen, D; Cui, QC; Dou, QP; Kong, D; Sarkar, FH, 2012
)
0.64
"The main reasons for the failure of most chemopreventive agents during clinical trials are poor in vivo bioavailability and dose-limiting side effects."( Chemoprevention of lung tumorigenesis by intranasally administered diindolylmethane in A/J mice.
Kassie, F; Melkamu, T; Qian, X; Song, JM; Upadhyaya, P, 2013
)
0.39
" Oral bioavailability of each compound ranged from 6% (C-DIM8) to 42% (C-DIM12)."( Neuroprotective efficacy and pharmacokinetic behavior of novel anti-inflammatory para-phenyl substituted diindolylmethanes in a mouse model of Parkinson's disease.
Colagiovanni, D; De Miranda, BR; Gustafson, DL; Hansen, RJ; Lunghofer, PJ; Miller, JA; Safe, S; Tjalkens, RB, 2013
)
0.39
" Caco-2 permeability studies resulted in poor permeability and poor oral bioavailability was demonstrated by pharmacokinetic studies."( Novel diindolylmethane derivatives based NLC formulations to improve the oral bioavailability and anticancer effects in triple negative breast cancer.
Doddapaneni, R; Godugu, C; Safe, SH; Singh, M, 2016
)
0.43
"The evaluation of the bioavailability of bioactive compounds from cruciferous foods is one challenge in the design of clinical trials for studying their functionality."( Bioavailability and new biomarkers of cruciferous sprouts consumption.
Baenas, N; García-Viguera, C; Moreno, DA; Suárez-Martínez, C, 2017
)
0.46
" Further in vivo studies were carried out to analyze the biodistribution of the drug, blood biochemical analysis and bioavailability of the drug."( Natural polymer functionalized graphene oxide for co-delivery of anticancer drugs: In-vitro and in-vivo.
Andrews, NG; Deb, A; Raghavan, V, 2018
)
0.48
" However, low stability and bioavailability limit its application."( Interactions between β-Lactoglobulin and 3,3'-Diindolylmethane in Model System.
Guo, M; Sun, X; Wang, C; Wang, H; Zhou, X, 2019
)
0.78
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
" I33' may have accounted for Vg increases observed in trout fed I3C as it is present in liver after oral dosing at concentrations (70 microM) expected to maximally induce Vg."( 3,3'-diindolylmethane, a major condensation product of indole-3-carbinol, is a potent estrogen in the rainbow trout.
Carlson, DB; Katchamart, S; Shilling, AD; Williams, DE, 2001
)
1.75
" The concentrations of DIM required to suppress CSCs formation are in the close range to those achievable in human plasma after oral dosing of the compound."( Diindolilmethane (DIM) selectively inhibits cancer stem cells.
Alakhov, V; Iourtchenco, L; Kiselev, V; Li, S; Liu, LF; Muyjnek, E; Semov, A; Su, X; Xu, Y, 2012
)
0.38
" We report that administration of DIM in a multidose schedule protected rodents against lethal doses of total body irradiation up to 13 Gy, whether DIM dosing was initiated before or up to 24 h after radiation."( DIM (3,3'-diindolylmethane) confers protection against ionizing radiation by a unique mechanism.
Brown, ML; Dritschilo, A; Fan, S; Jiao, Y; Meng, Q; Rosen, EM; Sarkar, FH; Xu, J; Zhang, X; Zhao, L, 2013
)
0.9
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Occurs in Manufacturing (29 Product(s))

Product Categories

Product CategoryProducts
Active Lifestyle & Fitness10
Pet Supplies1
Professional Supplements5
Vitamins & Supplements13

Products

ProductBrandCategoryCompounds Matched from IngredientsDate Retrieved
Action Labs DIM for Men - Alpha Advantage -- 30 VegCapsAction LabsActive Lifestyle & FitnessDiindolylmethane2024-11-29 10:47:42
ALLMAX Nutrition DIM -- 60 Veggie CapsulesALLMAX NutritionActive Lifestyle & Fitness3,3'-Diindolymethane2024-11-29 10:47:42
Animal Power Balance -- 30 PacksAnimalActive Lifestyle & FitnessDiindolylmethane, Biotin, Chromium, Folate, phytonadione, Vitamin K2024-11-29 10:47:42
Animal Stak All-in-1 Pill Packs -- 21 PacketsAnimalActive Lifestyle & FitnessDiindolylmethane, Astaxanthin, Coenzyme Q10, L-Glutamine, Glycine, Vitamin B6, Quercetin Dihydrate, Alpha-Lipoic Acid, Vitamin B62024-11-29 10:47:42
Bark & Whiskers Adrenal Support Supplement Powder for Dogs & Cats -- 3.17 ozBark & WhiskersPet SuppliesDiindolylmethane, Melatonin2024-11-29 10:47:42
Codeage Liposomal DIM-E - Diindolylmethane Antioxidant SGS Vitamin E Tocopherols & Isomers -- 120 CapsulesCodeageProfessional SupplementsDiindolylmethane, Gamma, Beta2024-11-29 10:47:42
Cutler Nutrition Triumph Testosterone Booster -- 56 Vegetarian CapsulesCutler NutritionActive Lifestyle & FitnessDiindolylmethane2024-11-29 10:47:42
DaVinci Laboratories DIMPRO -- 150 mg - 60 CapsulesDaVinci LaboratoriesProfessional Supplements diindolylmethane2024-11-29 10:47:42
DaVinci Laboratories DIMPRO -- 60 CapsulesDaVinci LaboratoriesProfessional Supplements diindolylmethane2024-11-29 10:47:42
DaVinci Laboratories Hair Effects™ -- 90 CapsulesDaVinci LaboratoriesProfessional Supplements diindolylmethane, Biotin, L-Cysteine, Methylsulfonylmethane, Gamma Linoleic Acid2024-11-29 10:47:42
Emerald Labs Estrogen Detox for Men and Women -- 60 Vegetable CapsEmerald LabsVitamins & SupplementsDiindolylmethane, Vitamin B122024-11-29 10:47:42
Evlution Nutrition DIM200 -- 60 Veggie CapsulesEvlution NutritionVitamins & SupplementsDiindolylmethane2024-11-29 10:47:42
Force Factor Fundalmentals DIM -- 30 CapsulesForce FactorActive Lifestyle & FitnessDIM, Selenium2024-11-29 10:47:42
Natural Factors WomenSense EstroSense® -- 60 Vegetarian CapsulesNatural FactorsVitamins & SupplementsDi-Indolylmethane, Curcumin, Microcrystalline cellulose, Indole-3-Carbinol, Lycopene, Carnosic Acid, Sulforaphane2024-11-29 10:47:42
Nutricost DIM Capsules -- 300 mg - 120 CapsulesNutricostVitamins & SupplementsDIM2024-11-29 10:47:42
Olympian Labs DIM -- 60 Vegetarian CapsulesOlympian LabsVitamins & SupplementsDIM, microcrystalline cellulose2024-11-29 10:47:42
Olympian Labs DIM-150 -- 30 Vegetarian CapsulesOlympian LabsVitamins & SupplementsDIM, microcrystalline cellulose2024-11-29 10:47:42
Olympian Labs PSN DIM -- 100 mg - 120 CapsulesOlympian LabsVitamins & SupplementsDIM, microcrystalline cellulose2024-11-29 10:47:42
Olympian Labs PSN DIM -- 150 mg - 30 Vegetarian CapsulesOlympian LabsVitamins & SupplementsDIM2024-11-29 10:47:42
Olympian Labs PSN DIM -- 250 mg - 30 CapsulesOlympian LabsActive Lifestyle & FitnessDIM, microcrystalline cellulose2024-11-29 10:47:42
Olympian Labs PSN DIM -- 250 mg - 30 Vegetarian CapsulesOlympian LabsVitamins & SupplementsDIM, microcrystalline cellulose2024-11-29 10:47:42
Olympian Labs PSN Testosterone Booster -- 60 CapsulesOlympian LabsActive Lifestyle & FitnessDIM, DHEA, microcrystalline cellulose, Vitamin B6, Vitamin B62024-11-29 10:47:42
Snap Supplements Testo Booster -- 60 CapsulesSnap SupplementsVitamins & SupplementsDiindolylmethane, Vitamin D3, Vitamin B32024-11-29 10:47:42
Source Naturals DIM -- 200 mg - 120 TabletsSource NaturalsVitamins & SupplementsDiindolylmethane, Vitamin E, Vitamin E, Microcrystalline cellulose, stearic acid2024-11-29 10:47:42
Source Naturals DIM -- 200 mg - 60 TabletsSource NaturalsVitamins & SupplementsDiindolylmethane, Vitamin E, Vitamin E, Microcrystalline cellulose, stearic acid2024-11-29 10:47:42
Sunwarrior Sport Active Creatine for Her Raspberry Elderberry Lemonade -- 14.1 ozSunwarriorActive Lifestyle & FitnessDIM, citric acid, citric acid, rebaudioside A2024-11-29 10:47:42
Thorne Research Hormone Advantage -- 60 CapsulesThorne ResearchProfessional SupplementsDiindolylmethane2024-11-29 10:47:42
Zhou Boost Elite® -- 90 Veggie CapsulesZhouActive Lifestyle & FitnessDiindolylmethane2024-11-29 10:47:42
Zhou DIM Active™ with Activated Broccoli Extract -- 60 Veggie CapsulesZhouVitamins & SupplementsDIM, Vitamin C, Vitamin E, Vitamin E2024-11-29 10:47:42

Roles (2)

RoleDescription
antineoplastic agentA substance that inhibits or prevents the proliferation of neoplasms.
P450 inhibitorAn enzyme inhibitor that interferes with the activity of cytochrome P450 involved in catalysis of organic substances.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
indolesAny compound containing an indole skeleton.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
indole glucosinolate activation (herbivore attack)320
indole glucosinolate activation (herbivore attack)424

Protein Targets (31)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, TYROSYL-DNA PHOSPHODIESTERASEHomo sapiens (human)Potency35.48130.004023.8416100.0000AID485290
Chain A, Ferritin light chainEquus caballus (horse)Potency11.22025.623417.292931.6228AID485281
USP1 protein, partialHomo sapiens (human)Potency56.23410.031637.5844354.8130AID504865
Microtubule-associated protein tauHomo sapiens (human)Potency29.00270.180013.557439.8107AID1460; AID1468
regulator of G-protein signaling 4Homo sapiens (human)Potency0.13370.531815.435837.6858AID504845
EWS/FLI fusion proteinHomo sapiens (human)Potency6.45140.001310.157742.8575AID1259252; AID1259253; AID1259255; AID1259256
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency17.01570.035520.977089.1251AID504332
vitamin D3 receptor isoform VDRAHomo sapiens (human)Potency50.11870.354828.065989.1251AID504847
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency39.81070.031610.279239.8107AID884; AID885
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
GABA theta subunitRattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Aryl hydrocarbon receptorMus musculus (house mouse)EC50 (µMol)78.00000.00000.00000.0000AID1527840
Aryl hydrocarbon receptorMus musculus (house mouse)Kd0.09000.00080.04540.0900AID1527833
Nuclear receptor ROR-gammaHomo sapiens (human)EC50 (µMol)78.00000.02000.70359.0000AID1527840
G-protein coupled receptor 84Mus musculus (house mouse)EC50 (µMol)4.27004.27004.27004.2700AID1707050
G-protein coupled receptor 84Homo sapiens (human)EC50 (µMol)3.31290.08903.868710.0000AID1447407; AID1447408; AID1447416; AID1447417; AID1447418; AID1447419; AID1546371; AID1546372; AID1546374; AID1546376; AID1546378; AID1546389; AID1546390; AID1546392
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
G-protein coupled receptor 84Homo sapiens (human)Kb0.88000.88000.88000.8800AID1447422
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (15)

Processvia Protein(s)Taxonomy
negative regulation of transcription by RNA polymerase IINuclear receptor ROR-gammaHomo sapiens (human)
xenobiotic metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
regulation of glucose metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
regulation of steroid metabolic processNuclear receptor ROR-gammaHomo sapiens (human)
intracellular receptor signaling pathwayNuclear receptor ROR-gammaHomo sapiens (human)
circadian regulation of gene expressionNuclear receptor ROR-gammaHomo sapiens (human)
cellular response to sterolNuclear receptor ROR-gammaHomo sapiens (human)
positive regulation of circadian rhythmNuclear receptor ROR-gammaHomo sapiens (human)
regulation of fat cell differentiationNuclear receptor ROR-gammaHomo sapiens (human)
positive regulation of DNA-templated transcriptionNuclear receptor ROR-gammaHomo sapiens (human)
adipose tissue developmentNuclear receptor ROR-gammaHomo sapiens (human)
T-helper 17 cell differentiationNuclear receptor ROR-gammaHomo sapiens (human)
regulation of transcription by RNA polymerase IINuclear receptor ROR-gammaHomo sapiens (human)
biological_processG-protein coupled receptor 84Homo sapiens (human)
neuropeptide signaling pathwayG-protein coupled receptor 84Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (11)

Processvia Protein(s)Taxonomy
RNA polymerase II cis-regulatory region sequence-specific DNA bindingNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificNuclear receptor ROR-gammaHomo sapiens (human)
DNA-binding transcription factor activityNuclear receptor ROR-gammaHomo sapiens (human)
protein bindingNuclear receptor ROR-gammaHomo sapiens (human)
oxysterol bindingNuclear receptor ROR-gammaHomo sapiens (human)
zinc ion bindingNuclear receptor ROR-gammaHomo sapiens (human)
ligand-activated transcription factor activityNuclear receptor ROR-gammaHomo sapiens (human)
sequence-specific double-stranded DNA bindingNuclear receptor ROR-gammaHomo sapiens (human)
nuclear receptor activityNuclear receptor ROR-gammaHomo sapiens (human)
urotensin II receptor activityG-protein coupled receptor 84Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (8)

Processvia Protein(s)Taxonomy
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
nucleusNuclear receptor ROR-gammaHomo sapiens (human)
nucleoplasmNuclear receptor ROR-gammaHomo sapiens (human)
nuclear bodyNuclear receptor ROR-gammaHomo sapiens (human)
chromatinNuclear receptor ROR-gammaHomo sapiens (human)
nucleusNuclear receptor ROR-gammaHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
plasma membraneG-protein coupled receptor 84Homo sapiens (human)
specific granule membraneG-protein coupled receptor 84Homo sapiens (human)
tertiary granule membraneG-protein coupled receptor 84Homo sapiens (human)
receptor complexG-protein coupled receptor 84Homo sapiens (human)
plasma membraneG-protein coupled receptor 84Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (139)

Assay IDTitleYearJournalArticle
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1447429Activation of AhR in human HepG2 cells assessed as induction of CYP1A1 mRNA expression after 18 hrs by RT-PCR method
AID582000Binding affinity to recombinant wild type Leishmania donovani AG83 topoisomerase 1b after 24 hrs by equilibrium dialysis method2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Topoisomerase I gene mutations at F270 in the large subunit and N184 in the small subunit contribute to the resistance mechanism of the unicellular parasite Leishmania donovani towards 3,3'-diindolylmethane.
AID582003Binding affinity to recombinant drug-resistant Leishmania donovani LdDR50 topoisomerase 1b large subunit F270L, K430N mutant after 24 hrs by equilibrium dialysis method2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Topoisomerase I gene mutations at F270 in the large subunit and N184 in the small subunit contribute to the resistance mechanism of the unicellular parasite Leishmania donovani towards 3,3'-diindolylmethane.
AID308569Growth promoting activity in Oryza sativa assessed as shoot length at 125 ppm on day 52007Bioorganic & medicinal chemistry letters, Sep-01, Volume: 17, Issue:17
Eco-friendly synthesis and study of new plant growth promoters: 3,3'-Diindolylmethane and its derivatives.
AID581976Antimicrobial activity against wild type Leishmania donovani AG83 transfected with drug-resistant Leishmania donovani LdDR50 topoisomerase 1 F270L, K430N mutant in large subunit and N184S mutant in small subunit assessed as inhibition of parasite growth a2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Topoisomerase I gene mutations at F270 in the large subunit and N184 in the small subunit contribute to the resistance mechanism of the unicellular parasite Leishmania donovani towards 3,3'-diindolylmethane.
AID1546378Agonist activity at human Gi1alpha-coupled GPR84 expressed in baculovirus infected Sf9 insect cells assessed as stimulation of [35S]GTPgammaS binding measured after 30 mins by liquid scintillation counting method2020Journal of medicinal chemistry, 03-12, Volume: 63, Issue:5
An Agonist Radioligand for the Proinflammatory Lipid-Activated G Protein-Coupled Receptor GPR84 Providing Structural Insights.
AID1546371Agonist activity at human N-terminal FLAG-tagged GPR84 receptor stably expressed in CHO cells assessed as inhibition of forskolin-induced cAMP production preincubated for 20 mins followed by forskolin addition and measured after 20 mins2020Journal of medicinal chemistry, 03-12, Volume: 63, Issue:5
An Agonist Radioligand for the Proinflammatory Lipid-Activated G Protein-Coupled Receptor GPR84 Providing Structural Insights.
AID398042Antifungal activity against Mucor miehei by agar diffusion method2003Journal of natural products, Nov, Volume: 66, Issue:11
New indole alkaloids from the North Sea bacterium Vibrio parahaemolyticus Bio249.
AID581987Inhibition of recombinant drug-resistant Leishmania donovani LdDR50 topoisomerase 1b large subunit F270L mutant and small subunit N184S mutant-mediated relaxation of supercoiled pBluescript SK(+) DNA at up to 50 uM after 30 mins using ethidium bromide sta2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Topoisomerase I gene mutations at F270 in the large subunit and N184 in the small subunit contribute to the resistance mechanism of the unicellular parasite Leishmania donovani towards 3,3'-diindolylmethane.
AID582001Ratio of KD for drug-resistant Leishmania donovani LdDR50 topoisomerase 1b to KD for wild type Leishmania donovani AG83 topoisomerase 1b2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Topoisomerase I gene mutations at F270 in the large subunit and N184 in the small subunit contribute to the resistance mechanism of the unicellular parasite Leishmania donovani towards 3,3'-diindolylmethane.
AID581855Antimicrobial activity against wild type Leishmania donovani AG83 transfected with drug-resistant Leishmania donovani LdDR50 topoisomerase 1 F270L, N184S mutant in large subunit assessed as inhibition of parasite growth at 20 uM after 24 hrs by MTT assay2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Topoisomerase I gene mutations at F270 in the large subunit and N184 in the small subunit contribute to the resistance mechanism of the unicellular parasite Leishmania donovani towards 3,3'-diindolylmethane.
AID1447425Agonist activity at human FFAR4 expressed in CHO cells assessed as beta-arrestin recruitment at 10 uM after 90 mins by beta-galactosidase complementation assay
AID398038Antibacterial activity against Staphylococcus aureus by agar diffusion method2003Journal of natural products, Nov, Volume: 66, Issue:11
New indole alkaloids from the North Sea bacterium Vibrio parahaemolyticus Bio249.
AID308566Growth promoting activity in Oryza sativa assessed as root length at 31.25 ppm on day 52007Bioorganic & medicinal chemistry letters, Sep-01, Volume: 17, Issue:17
Eco-friendly synthesis and study of new plant growth promoters: 3,3'-Diindolylmethane and its derivatives.
AID581985Inhibition of recombinant drug-resistant Leishmania donovani LdDR50 topoisomerase 1b wild type small subunit and large subunit F270L mutant-mediated relaxation of supercoiled pBluescript SK(+) DNA at up to 50 uM after 30 mins using ethidium bromide staini2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Topoisomerase I gene mutations at F270 in the large subunit and N184 in the small subunit contribute to the resistance mechanism of the unicellular parasite Leishmania donovani towards 3,3'-diindolylmethane.
AID581982Inhibition of recombinant drug-resistant Leishmania donovani LdDR50 topoisomerase 1b-mediated relaxation of supercoiled pBluescript SK(+) DNA at up to 50 uM after 30 mins using ethidium bromide staining2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Topoisomerase I gene mutations at F270 in the large subunit and N184 in the small subunit contribute to the resistance mechanism of the unicellular parasite Leishmania donovani towards 3,3'-diindolylmethane.
AID581981Antimicrobial activity against wild type Leishmania donovani AG83 transfected with drug-resistant Leishmania donovani LdDR50 topoisomerase 1 wild type large subunit and N184S mutant in small subunit assessed as inhibition of parasite growth at 20 uM after2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Topoisomerase I gene mutations at F270 in the large subunit and N184 in the small subunit contribute to the resistance mechanism of the unicellular parasite Leishmania donovani towards 3,3'-diindolylmethane.
AID581854Antimicrobial activity against wild type Leishmania donovani AG83 assessed as inhibition of parasite growth after 24 hrs by MTT assay2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Topoisomerase I gene mutations at F270 in the large subunit and N184 in the small subunit contribute to the resistance mechanism of the unicellular parasite Leishmania donovani towards 3,3'-diindolylmethane.
AID581978Drug uptake in wild type Leishmania donovani AG83 at 20 uM after 30 mins by spectrophotometric analysis2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Topoisomerase I gene mutations at F270 in the large subunit and N184 in the small subunit contribute to the resistance mechanism of the unicellular parasite Leishmania donovani towards 3,3'-diindolylmethane.
AID1447408Agonist activity at human GPR84 expressed in CHO cells assessed as beta-arrestin recruitment after 90 mins by beta-galactosidase complementation assay
AID581997Inhibition of recombinant Leishmania donovani AG83 topoisomerase 1b-mediated religation of 14-mer/25-mer suicide DNA substrate at 20 uM after 120 mins by PAGE analysis2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Topoisomerase I gene mutations at F270 in the large subunit and N184 in the small subunit contribute to the resistance mechanism of the unicellular parasite Leishmania donovani towards 3,3'-diindolylmethane.
AID581989Inhibition of recombinant drug-resistant Leishmania donovani LdDR50 topoisomerase 1b large subunit K430N mutant and small subunit N184S mutant-mediated relaxation of supercoiled pBluescript SK(+) DNA at up to 50 uM after 30 mins using ethidium bromide sta2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Topoisomerase I gene mutations at F270 in the large subunit and N184 in the small subunit contribute to the resistance mechanism of the unicellular parasite Leishmania donovani towards 3,3'-diindolylmethane.
AID581998Inhibition of recombinant drug-resistant Leishmania donovani LdDR50 topoisomerase 1b small subunit N184S mutant-mediated religation of 14-mer/25-mer suicide DNA substrate at 20 uM after 120 mins by PAGE analysis2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Topoisomerase I gene mutations at F270 in the large subunit and N184 in the small subunit contribute to the resistance mechanism of the unicellular parasite Leishmania donovani towards 3,3'-diindolylmethane.
AID1546389Agonist activity at recombinant human HA-tagged GPR84 stably expressed in HEK293 cells assessed as stimulation of [35S]GTPgammaS binding measured after 30 mins by liquid scintillation counting method2020Journal of medicinal chemistry, 03-12, Volume: 63, Issue:5
An Agonist Radioligand for the Proinflammatory Lipid-Activated G Protein-Coupled Receptor GPR84 Providing Structural Insights.
AID582007Binding affinity to Leishmania donovani small subunit of topoisomerase 1b2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Topoisomerase I gene mutations at F270 in the large subunit and N184 in the small subunit contribute to the resistance mechanism of the unicellular parasite Leishmania donovani towards 3,3'-diindolylmethane.
AID1447416Positive allosteric modulation of Gi coupled human GPR84 expressed in CHO cells assessed as potentiation of decanoic acid-induced inhibition of forskolin-induced cAMP accumulation by measuring decanoic acid EC50 at 0.1 uM after 15 mins in presence of [3H]
AID660428Growth inhibition of human MCF7 cells after 48 hrs by MTT assay2012Journal of medicinal chemistry, Feb-23, Volume: 55, Issue:4
Synthesis and evaluation of the cytotoxicities of tetraindoles: observation that the 5-hydroxy tetraindole (SK228) induces G₂ arrest and apoptosis in human breast cancer cells.
AID697853Inhibition of horse BChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID308576Growth promoting activity in Oryza sativa assessed as root length at 1000 ppm on day 52007Bioorganic & medicinal chemistry letters, Sep-01, Volume: 17, Issue:17
Eco-friendly synthesis and study of new plant growth promoters: 3,3'-Diindolylmethane and its derivatives.
AID697852Inhibition of electric eel AChE at 2 mg/ml by Ellman's method2012Bioorganic & medicinal chemistry, Nov-15, Volume: 20, Issue:22
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
AID581988Inhibition of recombinant drug-resistant Leishmania donovani LdDR50 topoisomerase 1b wild type small subunit and large subunit K430N mutant-mediated relaxation of supercoiled pBluescript SK(+) DNA at up to 50 uM after 30 mins using ethidium bromide staini2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Topoisomerase I gene mutations at F270 in the large subunit and N184 in the small subunit contribute to the resistance mechanism of the unicellular parasite Leishmania donovani towards 3,3'-diindolylmethane.
AID581980Antimicrobial activity against wild type Leishmania donovani AG83 transfected with drug-resistant Leishmania donovani LdDR50 topoisomerase 1 K430N mutant in large subunit and wild type small subunit assessed as inhibition of parasite growth at 20 uM after2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Topoisomerase I gene mutations at F270 in the large subunit and N184 in the small subunit contribute to the resistance mechanism of the unicellular parasite Leishmania donovani towards 3,3'-diindolylmethane.
AID581979Antimicrobial activity against wild type Leishmania donovani AG83 transfected with drug-resistant Leishmania donovani LdDR50 topoisomerase 1 K430N mutant in large subunit and N184S mutant in small subunit assessed as inhibition of parasite growth at 20 uM2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Topoisomerase I gene mutations at F270 in the large subunit and N184 in the small subunit contribute to the resistance mechanism of the unicellular parasite Leishmania donovani towards 3,3'-diindolylmethane.
AID398039Antibacterial activity against Bacillus subtilis by agar diffusion method2003Journal of natural products, Nov, Volume: 66, Issue:11
New indole alkaloids from the North Sea bacterium Vibrio parahaemolyticus Bio249.
AID436767Cytotoxicity against human ME18 cells for 48 hrs by MTT assay2009European journal of medicinal chemistry, Oct, Volume: 44, Issue:10
Novel 3,3'-diindolylmethane derivatives: synthesis and cytotoxicity, structural characterization in solid state.
AID398040Antibacterial activity against Streptomyces viridochromogenes by agar diffusion method2003Journal of natural products, Nov, Volume: 66, Issue:11
New indole alkaloids from the North Sea bacterium Vibrio parahaemolyticus Bio249.
AID1447419Positive allosteric modulation of Gi coupled human GPR84 expressed in CHO cells assessed as potentiation of decanoic acid-induced inhibition of forskolin-induced cAMP accumulation by measuring decanoic acid EC50 at 3 uM after 15 mins in presence of [3H]-c
AID1447427Antagonist activity at human FFAR4 expressed in CHO cells assessed as inhibition of TUG-89-induced beta-arrestin recruitment at 10 uM preincubated for 30 mins followed by TUG-89 addition measured after 90 mins by beta-galactosidase complementation assay
AID1546391Positive allosteric modulation of recombinant human GPR84 expressed in CHO cell membranes co-expressing beta-arrestin2 assessed as increase in [3H]PSB-1584 binding measured after 6 hrs by scintillation counting method relative to control2020Journal of medicinal chemistry, 03-12, Volume: 63, Issue:5
An Agonist Radioligand for the Proinflammatory Lipid-Activated G Protein-Coupled Receptor GPR84 Providing Structural Insights.
AID1447406Agonist activity at Gi coupled human GPR84 expressed in CHO cells assessed as inhibition of forskolin-induced cAMP accumulation at 10 uM after 15 mins in presence of [3H]-cAMP by radiometric assay relative to decanoic acid
AID1447438Stability of the compound in pH 1.2 artificial gastric fluid containing HCl, NaCl and pepsin assessed as parent compound remaining at 100 uM after 2 hrs by HPLC-MS analysis
AID1447424Agonist activity at Gq protein coupled human FFAR1 expressed in human 1321N1 cells assessed as induction of intracellular calcium level at 10 uM measured at 1.2 secs time interval by Fluo-4-AM dye based fluorescence assay
AID1439693Cytotoxicity against human U87 cells assessed as decrease in cell proliferation after 72 hrs by SRB assay2017Bioorganic & medicinal chemistry letters, 04-01, Volume: 27, Issue:7
Preliminary SAR on indole-3-carbinol and related fragments reveals a novel anticancer lead compound against resistant glioblastoma cells.
AID581856Antimicrobial activity against wild type Leishmania donovani AG83 transfected with drug-resistant Leishmania donovani LdDR50 topoisomerase 1 F270L, K430N mutant in large subunit assessed as inhibition of parasite growth at 20 uM after 24 hrs by MTT assay2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Topoisomerase I gene mutations at F270 in the large subunit and N184 in the small subunit contribute to the resistance mechanism of the unicellular parasite Leishmania donovani towards 3,3'-diindolylmethane.
AID1447435Stability of the compound in 1 mM sodium hydroxide solution at 100 uM at pH 11 up to 24 hrs by HPLC-MS analysis
AID1527833Displacement of 2-azido-3-[125I]7,8-dibromodibenzo-pdioxin from C57BL/6J mouse liver AhR2020European journal of medicinal chemistry, Jan-01, Volume: 185Targeting Aryl hydrocarbon receptor for next-generation immunotherapies: Selective modulators (SAhRMs) versus rapidly metabolized ligands (RMAhRLs).
AID581852Ratio of antimicrobial activity against drug-resistant Leishmania donovani LdDR50 to antimicrobial activity against wild type Leishmania donovani AG832009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Topoisomerase I gene mutations at F270 in the large subunit and N184 in the small subunit contribute to the resistance mechanism of the unicellular parasite Leishmania donovani towards 3,3'-diindolylmethane.
AID581994Effect on recombinant drug-resistant Leishmania donovani LdDR50 topoisomerase 1b small subunit N184S mutant-mediated cleavage of 25-mer duplex oligonucleotide at 5 uM after 30 mins by PAGE analysis2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Topoisomerase I gene mutations at F270 in the large subunit and N184 in the small subunit contribute to the resistance mechanism of the unicellular parasite Leishmania donovani towards 3,3'-diindolylmethane.
AID436769Cytotoxicity against human WS1 cells for 48 hrs by MTT assay2009European journal of medicinal chemistry, Oct, Volume: 44, Issue:10
Novel 3,3'-diindolylmethane derivatives: synthesis and cytotoxicity, structural characterization in solid state.
AID398037Antibacterial activity against Escherichia coli by agar diffusion method2003Journal of natural products, Nov, Volume: 66, Issue:11
New indole alkaloids from the North Sea bacterium Vibrio parahaemolyticus Bio249.
AID581991Effect on recombinant wild type Leishmania donovani AG83 topoisomerase 1b-mediated cleavage of 25-mer duplex oligonucleotide at 20 uM after 30 mins by PAGE analysis2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Topoisomerase I gene mutations at F270 in the large subunit and N184 in the small subunit contribute to the resistance mechanism of the unicellular parasite Leishmania donovani towards 3,3'-diindolylmethane.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID582006Binding affinity to Leishmania donovani large subunit of topoisomerase 1b2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Topoisomerase I gene mutations at F270 in the large subunit and N184 in the small subunit contribute to the resistance mechanism of the unicellular parasite Leishmania donovani towards 3,3'-diindolylmethane.
AID581993Effect on recombinant drug-resistant Leishmania donovani LdDR50 topoisomerase 1b large subunit K430N mutant-mediated cleavage of 25-mer duplex oligonucleotide at 20 uM after 30 mins by PAGE analysis2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Topoisomerase I gene mutations at F270 in the large subunit and N184 in the small subunit contribute to the resistance mechanism of the unicellular parasite Leishmania donovani towards 3,3'-diindolylmethane.
AID1447439Stability of the compound in pH 1.2 artificial gastric fluid containing HCl, NaCl and pepsin assessed as parent compound remaining at 100 uM after 4 hrs by HPLC-MS analysis
AID1447418Positive allosteric modulation of Gi coupled human GPR84 expressed in CHO cells assessed as potentiation of decanoic acid-induced inhibition of forskolin-induced cAMP accumulation by measuring decanoic acid EC50 at 1 uM after 15 mins in presence of [3H]-c
AID1546392Positive allosteric modulation of recombinant human GPR84 expressed in CHO cell membranes co-expressing beta-arrestin2 assessed as increase in [3H]PSB-1584 binding measured after 6 hrs by scintillation counting method2020Journal of medicinal chemistry, 03-12, Volume: 63, Issue:5
An Agonist Radioligand for the Proinflammatory Lipid-Activated G Protein-Coupled Receptor GPR84 Providing Structural Insights.
AID1447407Agonist activity at Gi coupled human GPR84 expressed in CHO cells assessed as inhibition of forskolin-induced cAMP accumulation after 15 mins in presence of [3H]-cAMP by radiometric assay
AID1439694Cytotoxicity against human U251 cells assessed as decrease in cell proliferation after 72 hrs by SRB assay2017Bioorganic & medicinal chemistry letters, 04-01, Volume: 27, Issue:7
Preliminary SAR on indole-3-carbinol and related fragments reveals a novel anticancer lead compound against resistant glioblastoma cells.
AID398041Antifungal activity against Candida albicans by agar diffusion method2003Journal of natural products, Nov, Volume: 66, Issue:11
New indole alkaloids from the North Sea bacterium Vibrio parahaemolyticus Bio249.
AID308574Growth promoting activity in Oryza sativa assessed as root length at 500 ppm on day 52007Bioorganic & medicinal chemistry letters, Sep-01, Volume: 17, Issue:17
Eco-friendly synthesis and study of new plant growth promoters: 3,3'-Diindolylmethane and its derivatives.
AID581983Inhibition of recombinant wild type Leishmania donovani AG83 topoisomerase 1b-mediated relaxation of supercoiled pBluescript SK(+) DNA at 10 uM after 30 mins using ethidium bromide staining2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Topoisomerase I gene mutations at F270 in the large subunit and N184 in the small subunit contribute to the resistance mechanism of the unicellular parasite Leishmania donovani towards 3,3'-diindolylmethane.
AID581857Antimicrobial activity against wild type Leishmania donovani AG83 transfected with drug-resistant Leishmania donovani LdDR50 topoisomerase 1 F270Lmutant in large subunit assessed as inhibition of parasite growth at 20 uM after 24 hrs by MTT assay2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Topoisomerase I gene mutations at F270 in the large subunit and N184 in the small subunit contribute to the resistance mechanism of the unicellular parasite Leishmania donovani towards 3,3'-diindolylmethane.
AID582004Binding affinity to recombinant drug-resistant Leishmania donovani LdDR50 topoisomerase 1b large subunit F270L mutant after 24 hrs by equilibrium dialysis method2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Topoisomerase I gene mutations at F270 in the large subunit and N184 in the small subunit contribute to the resistance mechanism of the unicellular parasite Leishmania donovani towards 3,3'-diindolylmethane.
AID308567Growth promoting activity in Oryza sativa assessed as shoot length at 62.5 ppm on day 52007Bioorganic & medicinal chemistry letters, Sep-01, Volume: 17, Issue:17
Eco-friendly synthesis and study of new plant growth promoters: 3,3'-Diindolylmethane and its derivatives.
AID1546369Displacement of [3H]PSB-1584 from recombinant human GPR84 expressed in CHO cell membranes co-expressing beta-arrestin2 measured after 6 hrs by scintillation counting method2020Journal of medicinal chemistry, 03-12, Volume: 63, Issue:5
An Agonist Radioligand for the Proinflammatory Lipid-Activated G Protein-Coupled Receptor GPR84 Providing Structural Insights.
AID1447437Stability of the compound in pH 1.2 artificial gastric fluid containing HCl, NaCl and pepsin assessed as parent compound remaining at 100 uM after 1 hr by HPLC-MS analysis
AID1546372Agonist activity at human N-terminal FLAG-tagged GPR84 receptor stably expressed in CHO cell membranes assessed as stimulation of [35S]GTPgammaS binding incubated for 1 hr by liquid scintillation counting method2020Journal of medicinal chemistry, 03-12, Volume: 63, Issue:5
An Agonist Radioligand for the Proinflammatory Lipid-Activated G Protein-Coupled Receptor GPR84 Providing Structural Insights.
AID1439695Cytotoxicity against human IN1472 cells assessed as decrease in cell proliferation after 72 hrs by SRB assay2017Bioorganic & medicinal chemistry letters, 04-01, Volume: 27, Issue:7
Preliminary SAR on indole-3-carbinol and related fragments reveals a novel anticancer lead compound against resistant glioblastoma cells.
AID660427Growth inhibition of human MDA-MB-231 cells after 48 hrs by MTT assay2012Journal of medicinal chemistry, Feb-23, Volume: 55, Issue:4
Synthesis and evaluation of the cytotoxicities of tetraindoles: observation that the 5-hydroxy tetraindole (SK228) induces G₂ arrest and apoptosis in human breast cancer cells.
AID1447428Agonist activity at human GPR35 at 10 uM
AID1546376Agonist activity at recombinant human N-terminal epitope tagged/C-terminal eYFP-fused FLAG-tagged GPR84 expressed in Flp-In TREx 293 cell membranes assessed as inhibition of forskolin-induced cAMP production measured after 30 mins by HTRF assay2020Journal of medicinal chemistry, 03-12, Volume: 63, Issue:5
An Agonist Radioligand for the Proinflammatory Lipid-Activated G Protein-Coupled Receptor GPR84 Providing Structural Insights.
AID581990Inhibition of recombinant drug-resistant Leishmania donovani LdDR50 topoisomerase 1b wild type large subunit and small subunit N184S mutant-mediated relaxation of supercoiled pBluescript SK(+) DNA at up to 50 uM after 30 mins using ethidium bromide staini2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Topoisomerase I gene mutations at F270 in the large subunit and N184 in the small subunit contribute to the resistance mechanism of the unicellular parasite Leishmania donovani towards 3,3'-diindolylmethane.
AID581995Effect on recombinant drug-resistant Leishmania donovani LdDR50 topoisomerase 1b small subunit N184S mutant-mediated cleavage of 25-mer duplex oligonucleotide at 20 uM after 30 mins by PAGE analysis2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Topoisomerase I gene mutations at F270 in the large subunit and N184 in the small subunit contribute to the resistance mechanism of the unicellular parasite Leishmania donovani towards 3,3'-diindolylmethane.
AID581986Inhibition of recombinant drug-resistant Leishmania donovani LdDR50 topoisomerase 1b wild type small subunit and large subunit F270L, K430N mutant-mediated relaxation of supercoiled pBluescript SK(+) DNA at up to 50 uM after 30 mins using ethidium bromide2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Topoisomerase I gene mutations at F270 in the large subunit and N184 in the small subunit contribute to the resistance mechanism of the unicellular parasite Leishmania donovani towards 3,3'-diindolylmethane.
AID292177Antitumor activity against MCF7 cells2007Journal of medicinal chemistry, Jul-26, Volume: 50, Issue:15
Computer-aided rational drug design: a novel agent (SR13668) designed to mimic the unique anticancer mechanisms of dietary indole-3-carbinol to block Akt signaling.
AID308572Growth promoting activity in Oryza sativa assessed as root length at 250 ppm on day 52007Bioorganic & medicinal chemistry letters, Sep-01, Volume: 17, Issue:17
Eco-friendly synthesis and study of new plant growth promoters: 3,3'-Diindolylmethane and its derivatives.
AID1447414Ratio of EC50 for human GPR84 expressed in CHO cells assessed as beta-arrestin recruitment to EC50 for Gi coupled human GPR84 expressed in CHO cells assessed as inhibition of forskolin-induced cAMP accumulation
AID1447422Positive allosteric modulation of Gi coupled human GPR84 expressed in CHO cells assessed as potentiation of decanoic acid-induced inhibition of forskolin-induced cAMP accumulation by measuring decanoic acid Kb after 15 mins in presence of [3H]-cAMP by rad
AID581977Drug uptake in drug-resistant Leishmania donovani LdDR50 at 20 uM after 30 mins by spectrophotometric analysis2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Topoisomerase I gene mutations at F270 in the large subunit and N184 in the small subunit contribute to the resistance mechanism of the unicellular parasite Leishmania donovani towards 3,3'-diindolylmethane.
AID308573Growth promoting activity in Oryza sativa assessed as shoot length at 500 ppm on day 52007Bioorganic & medicinal chemistry letters, Sep-01, Volume: 17, Issue:17
Eco-friendly synthesis and study of new plant growth promoters: 3,3'-Diindolylmethane and its derivatives.
AID1439696Cytotoxicity against human IN1528 cells assessed as decrease in cell proliferation after 72 hrs by SRB assay2017Bioorganic & medicinal chemistry letters, 04-01, Volume: 27, Issue:7
Preliminary SAR on indole-3-carbinol and related fragments reveals a novel anticancer lead compound against resistant glioblastoma cells.
AID581992Effect on recombinant drug-resistant Leishmania donovani LdDR50 topoisomerase 1b large subunit F270L mutant-mediated cleavage of 25-mer duplex oligonucleotide at 20 uM after 30 mins by PAGE analysis2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Topoisomerase I gene mutations at F270 in the large subunit and N184 in the small subunit contribute to the resistance mechanism of the unicellular parasite Leishmania donovani towards 3,3'-diindolylmethane.
AID581996Inhibition of recombinant drug-resistant Leishmania donovani LdDR50 topoisomerase 1b large subunit F270L mutant-mediated religation of 14-mer/25-mer suicide DNA substrate at 20 uM after 120 mins by PAGE analysis2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Topoisomerase I gene mutations at F270 in the large subunit and N184 in the small subunit contribute to the resistance mechanism of the unicellular parasite Leishmania donovani towards 3,3'-diindolylmethane.
AID308570Growth promoting activity in Oryza sativa assessed as root length at 125 ppm on day 52007Bioorganic & medicinal chemistry letters, Sep-01, Volume: 17, Issue:17
Eco-friendly synthesis and study of new plant growth promoters: 3,3'-Diindolylmethane and its derivatives.
AID1447409Agonist activity at human GPR84 expressed in CHO cells assessed as beta-arrestin recruitment at 10 uM after 90 mins by beta-galactosidase complementation assay relative to embelin
AID1447412Effect on forskolin-induced cAMP accumulation in CHO cells preincubated for 5 mins followed by forskolin addition measured after 15 mins in presence of [3H]-cAMP by radiometric assay
AID308571Growth promoting activity in Oryza sativa assessed as shoot length at 250 ppm on day 52007Bioorganic & medicinal chemistry letters, Sep-01, Volume: 17, Issue:17
Eco-friendly synthesis and study of new plant growth promoters: 3,3'-Diindolylmethane and its derivatives.
AID1447434Stability of the compound in water at 100 uM up to 24 hrs by HPLC-MS analysis
AID1546390Agonist activity at human Gi1alpha-coupled GPR84 expressed in baculovirus infected Sf9 insect cells assessed as stimulation of [35S]GTPgammaS binding measured after 30 mins by top-count liquid scintillation counting method2020Journal of medicinal chemistry, 03-12, Volume: 63, Issue:5
An Agonist Radioligand for the Proinflammatory Lipid-Activated G Protein-Coupled Receptor GPR84 Providing Structural Insights.
AID436768Cytotoxicity against doxorubicin-resistant human ME18 cells for 48 hrs by MTT assay2009European journal of medicinal chemistry, Oct, Volume: 44, Issue:10
Novel 3,3'-diindolylmethane derivatives: synthesis and cytotoxicity, structural characterization in solid state.
AID1447436Stability of the compound in 0.01% ammonia solution at 100 uM at pH 9 up to 24 hrs by HPLC-MS analysis
AID582002Binding affinity to recombinant drug-resistant Leishmania donovani LdDR50 topoisomerase 1b large subunit F270L, K430N mutant and small subunit N184S mutant after 24 hrs by equilibrium dialysis method2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Topoisomerase I gene mutations at F270 in the large subunit and N184 in the small subunit contribute to the resistance mechanism of the unicellular parasite Leishmania donovani towards 3,3'-diindolylmethane.
AID582005Binding affinity to recombinant drug-resistant Leishmania donovani LdDR50 topoisomerase 1b small subunit N184S mutant after 24 hrs by equilibrium dialysis method2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Topoisomerase I gene mutations at F270 in the large subunit and N184 in the small subunit contribute to the resistance mechanism of the unicellular parasite Leishmania donovani towards 3,3'-diindolylmethane.
AID308565Growth promoting activity in Oryza sativa assessed as shoot length at 31.25 ppm on day 52007Bioorganic & medicinal chemistry letters, Sep-01, Volume: 17, Issue:17
Eco-friendly synthesis and study of new plant growth promoters: 3,3'-Diindolylmethane and its derivatives.
AID308575Growth promoting activity in Oryza sativa assessed as shoot length at 1000 ppm on day 52007Bioorganic & medicinal chemistry letters, Sep-01, Volume: 17, Issue:17
Eco-friendly synthesis and study of new plant growth promoters: 3,3'-Diindolylmethane and its derivatives.
AID581999Binding affinity to recombinant drug-resistant Leishmania donovani LdDR50 topoisomerase 1b after 24 hrs by equilibrium dialysis method2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Topoisomerase I gene mutations at F270 in the large subunit and N184 in the small subunit contribute to the resistance mechanism of the unicellular parasite Leishmania donovani towards 3,3'-diindolylmethane.
AID1447417Positive allosteric modulation of Gi coupled human GPR84 expressed in CHO cells assessed as potentiation of decanoic acid-induced inhibition of forskolin-induced cAMP accumulation by measuring decanoic acid EC50 at 0.3 uM after 15 mins in presence of [3H]
AID308568Growth promoting activity in Oryza sativa assessed as root length at 62.5 ppm on day 52007Bioorganic & medicinal chemistry letters, Sep-01, Volume: 17, Issue:17
Eco-friendly synthesis and study of new plant growth promoters: 3,3'-Diindolylmethane and its derivatives.
AID581984Inhibition of recombinant drug-resistant Leishmania donovani LdDR50 topoisomerase 1b large subunit F270L, K430N mutant and small subunit N184S mutant-mediated relaxation of supercoiled pBluescript SK(+) DNA at up to 50 uM after 30 mins using ethidium brom2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Topoisomerase I gene mutations at F270 in the large subunit and N184 in the small subunit contribute to the resistance mechanism of the unicellular parasite Leishmania donovani towards 3,3'-diindolylmethane.
AID1527840Displacement of 2-azido-3-[125I]7,8-dibromodibenzo-pdioxin from C57BL/6J mouse liver AhR relative to TCDD2020European journal of medicinal chemistry, Jan-01, Volume: 185Targeting Aryl hydrocarbon receptor for next-generation immunotherapies: Selective modulators (SAhRMs) versus rapidly metabolized ligands (RMAhRLs).
AID1546374Agonist activity at recombinant human N-terminal epitope tagged/C-terminal eYFP-fused FLAG-tagged GPR84 expressed in Flp-In TREx 293 cell membranes assessed as stimulation of [35S]GTPgammaS binding preincubated for 15 mins followed by [35S]GTPgammaS addit2020Journal of medicinal chemistry, 03-12, Volume: 63, Issue:5
An Agonist Radioligand for the Proinflammatory Lipid-Activated G Protein-Coupled Receptor GPR84 Providing Structural Insights.
AID1439697Cytotoxicity against human IN1760 cells assessed as decrease in cell proliferation after 72 hrs by SRB assay2017Bioorganic & medicinal chemistry letters, 04-01, Volume: 27, Issue:7
Preliminary SAR on indole-3-carbinol and related fragments reveals a novel anticancer lead compound against resistant glioblastoma cells.
AID1707050Agonist activity at mouse Galphai2-coupled GPR84 expressed in human Flp-In-T-REx-293 cell membrane assessed as stimulation of [35S]GTPgammaS binding incubated for 60 mins by liquid scintillation spectroscopy2020Journal of medicinal chemistry, 12-24, Volume: 63, Issue:24
Modulation of the G-Protein-Coupled Receptor 84 (GPR84) by Agonists and Antagonists.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID581853Antimicrobial activity against drug-resistant Leishmania donovani LdDR50 assessed as inhibition of parasite growth at up to 50 uM after 24 hrs by MTT assay2009Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6
Topoisomerase I gene mutations at F270 in the large subunit and N184 in the small subunit contribute to the resistance mechanism of the unicellular parasite Leishmania donovani towards 3,3'-diindolylmethane.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (399)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905 (1.25)18.7374
1990's12 (3.01)18.2507
2000's110 (27.57)29.6817
2010's224 (56.14)24.3611
2020's48 (12.03)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 26.07

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index26.07 (24.57)
Research Supply Index6.05 (2.92)
Research Growth Index5.57 (4.65)
Search Engine Demand Index60.87 (26.88)
Search Engine Supply Index3.98 (0.95)

This Compound (26.07)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials16 (3.91%)5.53%
Reviews23 (5.62%)6.00%
Case Studies4 (0.98%)4.05%
Observational0 (0.00%)0.25%
Other366 (89.49%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (15)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Single-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of 3,3'-Diindolylmethane (BR-DIM) in Patients With Systemic Lupus Erythematosus (SLE) [NCT02483624]Phase 16 participants (Actual)Interventional2016-01-31Terminated
A Nutritional Intervention to Decrease Breast Density Among Female BRCA Carriers -A Prospective Clinical Trial [NCT02197000]23 participants (Actual)Interventional2014-11-11Completed
Phase II Trial of B-DIM (DIM: 3,3 Diindolylmethane) on Intermediate Endpoint Biomarkers in Patients With Prostate Cancer Who Are Undergoing Prostatectomy [NCT00888654]Phase 241 participants (Actual)Interventional2009-08-31Completed
Evaluation of Diindolylmethane Supplementation to Modulate Tamoxifen Efficacy in Breast Cancer The Diindolylmethane Efficacy Study [NCT01391689]144 participants (Actual)Interventional2011-02-28Completed
Phase I Ascending Single Dose Pharmacokinetics (PK) and Safety Study of 3,3' Di-indolylmethane (DIM) [NCT00784394]Phase 120 participants (Actual)Interventional2004-04-30Completed
The Potential for Oral DIM Supplementation to Increase the Production of the BRCA1 Protein in BRCA1 Mutation Carriers [NCT01022333]Phase 1300 participants (Anticipated)Interventional2009-07-31Recruiting
The Effect of Food Supplements on Food Intake and Gut Hormone Levels [NCT04292236]20 participants (Actual)Interventional2019-02-22Completed
An Investigation Into the Effects of Diidolylmethane (BioResponse DIM®) Supplementation in Women With Low-Grade Cervical Cytological Abnormalities [CRISP-1] [NCT00462813]Phase 33,000 participants (Anticipated)Interventional2004-10-31Completed
Phase Ib Placebo-Controlled Trial of Diindolylmethane (BR-DIM) in the Study of the Modulation of Intermediate Endpoint Markers in Patients With Prostate Cancer Who Are Undergoing Prostatectomy [NCT00450229]Phase 145 participants (Actual)Interventional2007-02-28Completed
Phase 1 Multiple-Dose Safety, Pharmacokinetic, and Drug Interaction Clinical Study of Nutritional-Grade, Absorption-Enhanced DIM (BR-DIM) [NCT00392652]Phase 114 participants (Actual)Interventional2006-11-30Completed
Targeting FMO-Mediated TMAO Formation in Kidney Disease (TMAO) Study [NCT03152097]13 participants (Actual)Interventional2018-03-30Completed
Voice Preserving Therapy of Laryngeal Papilloma In Children [NCT00591305]1 participants (Actual)Interventional2007-09-30Terminated(stopped due to insufficient resource for recruitment)
Phase I Study of Bioresponse-dim in Non-Metastatic, Hormone-Refractory Prostate Cancer Patients With Rising Serum PSA [NCT00305747]Phase 112 participants (Actual)Interventional2005-08-31Completed
Diindolymethane: Anti-proliferation Agent in Thyroid Disease-Non-surgical Protocol [NCT01846364]Early Phase 17 participants (Actual)Interventional2006-11-30Terminated(stopped due to Lack of sufficient enrollment)
A Pilot Study of BR-DIM in Women With Stage II-III, Triple Negative, and Androgen Receptor Positive, Invasive Breast Cancer, Who Have Residual Disease Following Surgical Resection After Neoadjuvant Chemotherapy [NCT01612910]Phase 20 participants (Actual)Interventional2012-06-30Withdrawn(stopped due to Research cancelled.)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00591305 (3) [back to overview]Estradiol Level in Blood Post Treatment
NCT00591305 (3) [back to overview]Estradiol Level in Blood Pre Treatment
NCT00591305 (3) [back to overview]Number of Cases With Recurrence of Laryngeal Papilloma in 5 Months
NCT00888654 (3) [back to overview]Mean Level of Diindolylmethane in Prostate Tissue After Treatment
NCT00888654 (3) [back to overview]Levels of Androgen Receptor in Prostate Tissue
NCT00888654 (3) [back to overview]Serum Levels of PSA, Testosterone, and Diindolylmethane

Estradiol Level in Blood Post Treatment

determine side-effect by comparing Estradiol level in blood before and after treatment (NCT00591305)
Timeframe: 5 month

Interventionpg/ml (Number)
Intervention29

[back to top]

Estradiol Level in Blood Pre Treatment

determine side-effect by comparing Estradiol level in blood before and after treatment (NCT00591305)
Timeframe: Before treatment at baseline

Interventionpg/ml (Number)
Intervention20

[back to top]

Number of Cases With Recurrence of Laryngeal Papilloma in 5 Months

vocal lesion size and area after 5 month with surgery visible lesion found in >50% of the treated tissue area, after surgery (NCT00591305)
Timeframe: Recurrence of pailloma at 5 months

Interventioncase (Number)
Intervention1

[back to top]

Mean Level of Diindolylmethane in Prostate Tissue After Treatment

(NCT00888654)
Timeframe: Within the first 24 months after radical prostatectomy.

Interventionng/g (Mean)
B-Dim, Radical Prosatectomy14.2

[back to top]

Levels of Androgen Receptor in Prostate Tissue

Levels of androgen receptor in prostate tissue as measured by AR score (intensity x % cells stained), higher scores indicate higher levels of androgen receptor in prostate tissue. (NCT00888654)
Timeframe: Pre and post radical prostatectomy

InterventionAR score (intensity x % cells stained) (Mean)
Pre-BR-DIM Androgen ReceptorPost-BR-DIM Androgen Receptor
B-Dim, Radical Prosatectomy278245

[back to top]

Serum Levels of PSA, Testosterone, and Diindolylmethane

Serum levels of PSA, testosterone, and diindolylmethane (DIM) (NCT00888654)
Timeframe: Pre and post radical prostatectomy

Interventionng/ml (Median)
Pre-treatment PSAPost-treatment PSAPre-treatment TestosteronePost-treatment TestosteronePre-treatment DIMPost-treatment DIM
B-Dim, Radical Prosatectomy6.45.83013880.07.5

[back to top]